Alantolactone Attenuates Renal Fibrosis via Inhibition of Transforming Growth Factor β/Smad3 Signaling Pathway
Diabetes & Metabolism Journal · 31.01.2024 · 48 (1) · 72-82
DOI: 10.4093/dmj.2022.0231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 31.01.2024. Verfasst von Kyeong-Min Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biotechnology, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Korea. Hauptthemen laut MEDLINE: Kidney Diseases, Ureteral Obstruction, Lactones, Sesquiterpenes, Eudesmane. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daegu Gyeongbuk Institute of Science and Technology, National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Background
Renal fibrosis is characterized by the accumulation of extracellular matrix proteins and interstitial fibrosis. Alantolactone is known to exert anticancer, anti-inflammatory, antimicrobial and antifungal effects; however, its effects on renal fibrosis remains unknown. Here, we investigated whether alantolactone attenuates renal fibrosis in mice unilateral ureteral obstruction (UUO) and evaluated the effect of alantolactone on transforming growth factor (TGF) signaling pathway in renal cells.
Methods
To evaluate the therapeutic effect of alantolactone, cell counting kit-8 (CCK-8) assay, histological staining, Western blot analysis, and real-time quantitative polymerase chain reaction were performed in UUO kidneys in vivo and in TGF-β-treated renal cells in vitro.
Results
Alantolactone (0.25 to 4 µM) did not affect the viability of renal cells. Mice orally administered 5 mg/kg of alantolactone daily for 15 days did not show mortality or liver toxicity. Alantolactone decreased UUO-induced blood urea nitrogen and serum creatinine levels. In addition, it significantly alleviated renal tubulointerstitial damage and fibrosis and decreased collagen type I, fibronectin, and α-smooth muscle actin (α-SMA) expression in UUO kidneys. In NRK-49F cells, alantolactone inhibited TGF-βstimulated expression of fibronectin, collagen type I, plasminogen activator inhibitor-1 (PAI-1), and α-SMA. In HK-2 cells, alantolactone inhibited TGF-β-stimulated expression of collagen type I and PAI-1. Alantolactone inhibited UUO-induced phosphorylation of Smad3 in UUO kidneys. In addition, it not only decreased TGF-β secretion but also Smad3 phosphorylation and translocation to nucleus in both kidney cell lines.
Conclusion
Alantolactone improves renal fibrosis by inhibiting the TGF-β/Smad3 signaling pathway in obstructive nephropathy. Thus, alantolactone is a potential therapeutic agent for chronic kidney disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Biotechnology, Daegu Gyeongbuk Institute of Science and Technology, Daegu, Korea.
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Korea.
Förderung
- Daegu Gyeongbuk Institute of Science and Technology
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Lee, K. M., Hwang, Y. J., & Jung, G. S. (2024). Alantolactone Attenuates Renal Fibrosis via Inhibition of Transforming Growth Factor β/Smad3 Signaling Pathway. Diabetes & Metabolism Journal, 48(1), 72-82. https://doi.org/10.4093/dmj.2022.0231
Vancouver
Lee KM, Hwang YJ, Jung GS. Alantolactone Attenuates Renal Fibrosis via Inhibition of Transforming Growth Factor β/Smad3 Signaling Pathway. Diabetes & Metabolism Journal. 2024;48(1):72-82. doi:10.4093/dmj.2022.0231
BibTeX
@article{Lee2024,
author = {Lee, Kyeong-Min and Hwang, Yeo Jin and Jung, Gwon-Soo},
title = {Alantolactone Attenuates Renal Fibrosis via Inhibition of Transforming Growth Factor β/Smad3 Signaling Pathway},
journal = {Diabetes & Metabolism Journal},
year = {2024},
volume = {48},
number = {1},
pages = {72--82},
doi = {10.4093/dmj.2022.0231}
}
EUVIMED